| Current Price | $34.00 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $32.64 | P/E Ratio | 0.00 |
| Prev. Close | $34.00 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $32.01 - $34.37 | Volume | 195,318 |
| 52-Wk Range | $25.93 - $50.26 | Avg. Daily Vol. | 314,808 |
| Current Price | $34.00 | Mkt Cap | $1.4B |
|---|---|---|---|
| Open | $32.64 | P/E Ratio | 0.00 |
| Prev. Close | $34.00 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $32.01 - $34.37 | Volume | 195,318 |
| 52-Wk Range | $25.93 - $50.26 | Avg. Daily Vol. | 314,808 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about RGNX.
Recs
tking123
(70.10)
Submitted: 1/8/2021 12:55:00 PM :
Start Price:
$47.21
NASDAQ:RGNX Score:
-43.53
Small company targeting eye disease gene therapy. Its eye-disease treatment is being tested in people with wet age-related macular degeneration. This is a big market and the leaders are Roche and Regeneron Pharmaceuticals.....Keep an eye on this one.
Recs
findil
(94.12)
Submitted: 9/27/2018 12:08:01 PM :
Start Price:
$76.70
NASDAQ:RGNX Score:
-106.15
Love the optionality of partners and internal pipeline combined with a differentiated competitive advantage.
Recs
TMFEBCapital
(97.54)
Submitted: 7/12/2018 12:41:22 PM :
Start Price:
$74.85
NASDAQ:RGNX Score:
-111.99
Big risk, big reward. Data from phase 1 trials in wet AMD and HoFH are on tap later this year. Solid balance sheet helped by $100 million payment in June from Novartis tied to NVS acquisition of AveXis, which is developing AVXS-101, an SMA gene therapy using RGNX's viral vectors.
Find the members with the highest scoring picks in RGNX.
otherAquanaut (99.66) Score: +141.08
The Score Leader is the player with the highest score across all their picks in RGNX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| otherAquanaut | 99.66 |
|
|
3M | $9.61 | +253.80% | +112.71% | +141.08 | 0 Comment | |
| portefeuille | 98.55 | 3/24/2016 |
|
5Y | $9.85 | +245.18% | +116.63% | +128.55 | 0 Comment | |
| portefeuille2 | 98.92 | 9/12/2016 |
|
5Y | $12.82 | +165.21% | +106.62% | +58.60 | 0 Comment | |
| naughtyguy | 31.90 | 5/7/2021 |
|
5Y | $35.34 | -3.79% | +4.51% | +8.30 | 0 Comment | |
| efarev | 49.83 | 5/23/2017 |
|
5Y | $18.60 | +82.80% | +82.82% | -0.03 | 0 Comment | |
| StockFlyer | 69.55 | 9/21/2020 |
|
5Y | $29.83 | +13.98% | +34.73% | -20.75 | 0 Comment | |
| Stlongs | 60.60 | 8/17/2020 |
|
5Y | $32.06 | +6.05% | +29.83% | -23.78 | 0 Comment | |
| TMFSaintCroix | 99.65 | 1/22/2018 |
|
5Y | $27.15 | +25.23% | +55.72% | -30.49 | 0 Comment | |
| Dananator | 37.53 | 11/19/2020 |
|
5Y | $36.76 | -7.51% | +23.30% | -30.81 | 0 Comment | |
| yoman | 35.03 | 1/21/2021 |
|
5Y | $43.33 | -21.53% | +14.28% | -35.82 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
